Status epilepticus

Global Artificial Coma/Medically Induced Coma Market Forecast to 2030: Focus on Drug Type, Application and Distribution Channel - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 27, 2022
Health, General Health, Pfizer, Propofol, Laboratory, Stroke, CAGR, Pharmacy, Status epilepticus, Piramal Group, Environment, Viatris, Traumatic brain injury, Hikma Pharmaceuticals, Drug overdose, AstraZeneca, Coma, Pharmaceutical industry

The global artificial coma/medically induced coma market was valued at $640.17 million in 2020, and is projected to reach $868.63 million by 2030, registering a CAGR of 3.1%.

Key Points: 
  • The global artificial coma/medically induced coma market was valued at $640.17 million in 2020, and is projected to reach $868.63 million by 2030, registering a CAGR of 3.1%.
  • The global artificial coma/medically induced coma market is segmented on the basis of drug type, application, distribution channel, and region.
  • By application, the market is fragmented into status epilepticus, stroke, traumatic brain injury, brain infections, drug overdose, and others.
  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global artificial coma/medically induced coma market to identify the prevailing opportunities.

NEURELIS EXPANDS INTELLECTUAL PROPERTY ESTATE FOR VALTOCO®, A PATIENT-CENTRIC NASAL SPRAY FOR ACUTE TREATMENT OF EPISODES OF FREQUENT SEIZURE ACTIVITY

Retrieved on: 
Tuesday, April 26, 2022
Schizophrenia, Population, Somnolence, Science, CNS, Central nervous system, Patient, Review, Technology, Diazepam, History of United States patent law, Hemangioma, CIV, Benzodiazepine, Multimedia, FDA, Quality of life, Glaucoma, Adult, CCMS, Food, Mania, Benzyl alcohol, Suicidal ideation, AED, ROCK, Contraindication, Anticonvulsant, Disease, Coma, View, AND, Behavior, Schedule, Boxed warning, Metabolic acidosis, MD, Status epilepticus, Depression, Seizure, Safety, Therapy, Patent, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Brain, Death, SAN, Health, Headache, Drug, Epilepsy, Risk, Hypoventilation, Intraocular pressure, Pharmaceutical industry, Birth control, Medicine, Gustav Neuring

11,241,414 (the '414 Patent) for VALTOCO (diazepam nasal spray) CIV for acute treatment of episodes of frequent seizure activity in adult and pediatric patients age six and older.

Key Points: 
  • 11,241,414 (the '414 Patent) for VALTOCO (diazepam nasal spray) CIV for acute treatment of episodes of frequent seizure activity in adult and pediatric patients age six and older.
  • In the U.S., as many as 170,000 of these patients deal with acute episodes of frequent seizure activity, sometimes referred to as "seizure clusters" or ''acute repetitive seizures."
  • In 2020, the FDA approved Neurelis's VALTOCO(diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from an individual's usual seizure pattern in adult and pediatric patients 6 years of age and older.
  • Important Safety Information about VALTOCO:
    VALTOCO(diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 6 years of age and older.

PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

Retrieved on: 
Monday, April 25, 2022
CSE, Pain disorder, Investment, Clinical trial, ANDA, Lists of diseases, Lou, Research, RVV, Administration, Mescaline, Emergency, Food, Hospital, LSD, GLOBE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, DMT, Amyotrophy, Psilocybin, Mental health, Ketamine, Trial of the century, Account, Neurological disorder, Seizure, Company, OTCQB, Observational study, Patent, Status epilepticus, Analgesic, Chronic pain, Depression, Congress, CGMP, Lysergic acid diethylamide, Levodopa-induced dyskinesia, Anesthesia, Study, FDA, University, LTS, Holding, MDMA, Pharmaceutical industry, Generic drug, Fine chemical, Vaccine, Amyotrophic lateral sclerosis

TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today reported financial results for its third quarter ended February 28, 2022, and provided recent business highlights and update. All amounts are stated in Canadian dollars unless otherwise indicated. 

Key Points: 
  • Cash and cash equivalents totaled $10,165,170 and Investment totaled $1,666,667 for a total of $11,831,837 as at February 28, 2022; and
    Accounts payable and accrued liabilities totaled $140,947 as at February 28, 2022.
  • Entered into a research collaboration agreement with Revive Therapeutics Ltd. (CSE: RVV) (OTCQB: RVVTF) for the development of a psilocybin microneedle patch;
    Granted U.S. Patent No.
  • PharmaTher is developing and commercializing novel uses, delivery forms and formulations of ketamine and ketamine analogs.
  • Full results of the Study are expected to be submitted for presentation at a medical congress by June 2022.

Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders

Retrieved on: 
Tuesday, April 19, 2022
Drug development, Dravet syndrome, Pain, Ingestive behaviors, Indian stock exchange, Population, PTSD, Cannabidiol, Lists of diseases, Impulsivity, Fever, Epilepsy, Central nervous system, Brain, Psilocybin, Seizure, Fenfluramine, Company, 2-Methyl-5-hydroxytryptamine, Bright Minds In Action Learning Village, Depression, Status epilepticus, SCN1A, Nicotine, Disorder, DS, FDA, RSU 1, Pharmaceutical industry, Serotonin

VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, Dr. Revati Shreeniwas, Chief Medical Officer, Professor John McCorvy, PhD, Senior Advisor, and other key speakers will host a symposium on the recent therapeutic developments within the Dravet Syndrome landscape. The symposium will also include a panel with Key Opinion Leaders and a Q&A session. In addition, the Company and KOLs will also provide a developmental update on BMB-101, Bright Minds’ lead R&D program for the treatment of Dravet Syndrome.

Key Points: 
  • All securities issued are further subject to a hold period of four months and one day from the date of issuance.
  • BMB-101, a 5-HT2C selective and biased agonist, has demonstrated compelling activity in a host of in-vitro and in-vivo non-clinical tests.
  • Dravet syndrome is an epilepsy syndrome that begins in infancy or early childhood and can include a spectrum of symptoms ranging from mild to severe.
  • Dravet syndrome affects an estimated 1:15,700 individuals in the U.S., or 0.0064% of the population (Wu 2015).

NEURELIS ANNOUNCES THREE POSTER PRESENTATIONS AT THE 2022 ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY

Retrieved on: 
Monday, April 4, 2022
Risk, Intraocular pressure, Caregiver, Adult, Benzodiazepine, Contraindication, Quality of life, 2021 Essex County Council election, Glaucoma, Technology, Boxed warning, EEG, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Diazepam, CCMS, Behavior, Population, Seizure, Central nervous system, Schizophrenia, View, Mania, Benzyl alcohol, AED, Suicidal ideation, Brain, Science, Hospital, ROCK, Hemangioma, Therapy, Gaps, Death, Multimedia, AND, Somnolence, CNS, Medical Affairs Bureau, Anticonvulsant, Health, American Academy, SAN, FDA, Metabolic acidosis, Headache, Hypoventilation, Status epilepticus, Food, Coma, Drug, Safety, Schedule, AAN, Depression, Pharmaceutical industry, Medicine, Dietary supplement, Birth control, Gustav Neuring, Epilepsy, Patient

These presentations will highlight ease of use, quality of life, and timing of administration of VALTOCO.

Key Points: 
  • These presentations will highlight ease of use, quality of life, and timing of administration of VALTOCO.
  • Additional investigational analysis was done with the following AAN poster reporting:
    The majority (87%) of treatments in the long-term study used only a single dose over 24 hours.
  • In the instances where a second dose was administered, investigational analysis was performed on the timing of the dose.
  • Reaching this goal requires addressing gaps in seizure treatment and control," stated Adrian Rabinowicz, M.D., SVP Clinical Development and Medical Affairs.

SciSparc Announces Closing of New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases

Retrieved on: 
Thursday, March 31, 2022
Company, Private Securities Litigation Reform Act, Cancer, Human, Agitation, NASDAQ, Autism, Investment, Degenerative disease, Ownership, THC, Central nervous system, SEC, Research, Risk, Obligate carrier, Status epilepticus, Solute carrier family 25 member 22, Pain, Mitochondrial membrane transport protein, Intention, U.S. Securities and Exchange Commission, CBD, TEL, GLOBE, Tourette syndrome, Annual report, Alzheimer's disease, Pharmaceutical industry

In humans, the mitochondrial carrier family (Solute Carrier Family 25, SLC25) consists of 53 members and is the largest solute transporter.

Key Points: 
  • In humans, the mitochondrial carrier family (Solute Carrier Family 25, SLC25) consists of 53 members and is the largest solute transporter.
  • Pursuant to the terms of the JV Agreement, at closing, SciSparc delivered an initial amount of $700 thousands (out of a total investment amount of up to $1.7 million).
  • SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.
  • For example, SciSparc is using forward-looking statements when it discusses its potential future investments in the joint venture.

Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain

Retrieved on: 
Wednesday, March 30, 2022
Company, Private Securities Litigation Reform Act, Agitation, NASDAQ, Autism, Ben-Gurion University of the Negev, Chemical engineering, Central nervous system, IND, THC, Research, SEC, Risk, Coronavirus Scientific Advisory Board (Turkey), Status epilepticus, Medicine, Targeted drug delivery, Pain, Peripheral nervous system, Negev, Nanotechnology, Safety, Chronic pain, Intention, U.S. Securities and Exchange Commission, CBD, TEL, CB2, GLOBE, Physician, SAB, Tourette syndrome, Annual report, Alzheimer's disease, Technology, Cannabinoid, MIT, Pharmaceutical industry, Technion – Israel Institute of Technology

TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced the appointment of Professor Avi Schroeder as a member of the Company's Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroeder will advise the Company on the formulation development of SCI-160 to enhance the proprietary synthetic CB2 receptor agonist’s biological effect and extend effect duration.

Key Points: 
  • As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain.
  • Prof. Schroeder will advise the Company on the formulation development of SCI-160 to enhance the proprietary synthetic CB2 receptor agonists biological effect and extend effect duration.
  • The Company previously achieved positive results in a series of pre-clinical trials in which the efficacy and safety of SCI-160 was demonstrated in both acute and chronic pain.
  • Prof. Schroeder received three degrees in Chemical Engineering from the Ben-Gurion University of the Negev and his postdoctoral training took place at MIT.

Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility

Retrieved on: 
Thursday, March 31, 2022
Professional Services, Health, Finance, General Health, Pharmaceutical, Banking, Biotechnology, Oaktree Capital Management, Private Securities Litigation Reform Act, Company, Risk, Marinus, Behavior, CDD, Therapy, Seizure, Trial of the century, Forward-looking statement, Caregiver, Somnolence, Adult, GABAA, Office of the Assistant Secretary for Preparedness and Response, CNS, Research, Biomedical Advanced Research and Development Authority, Status epilepticus, Incidence, DNA repair-deficiency disorder, Human services, Anticonvulsant, Food, U.S. Securities and Exchange Commission, Assistant, U.S. Department of Commerce Office of Security, Oak Tree, Office of Inspector General, U.S. Department of Health and Human Services, Security (finance), New Drug Application, BARDA, IV, RAISE, AED, Medication, Ganaxolone, Epilepsy, RSE, Suicidal ideation, Brain, NDA, Development, Depression, FDA, Allergen, Patient, CDKL5, Pharmaceutical industry, Fever

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced it has received $30 million in funding under the existing Oaktree Capital Management, L.P. (Oaktree) credit agreement.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced it has received $30 million in funding under the existing Oaktree Capital Management, L.P. (Oaktree) credit agreement.
  • In May 2021, Marinus signed a credit financing agreement with Oaktree, a leader among global investment managers specializing in alternative investments.
  • Together with this $30 million drawdown, Marinus has drawn a total of $75 million in funding, including $15 million at signing of the credit financing agreement and $30 million upon the FDAs acceptance of the CDD NDA filing in September 2021.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Monday, March 21, 2022
Health, Other Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Oaktree Capital Management, Marinus, CDD, Therapy, Patent, Investment, Seizure, Growth, GAAP, Caregiver, Research, Status epilepticus, Commercial, Orion, U.S. Securities and Exchange Commission, Food, Government, Security (finance), BARDA, G&A, IV, Food and Drug Administration, Medication, Epilepsy, TSC, Ovid, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RSE, Biomedical Advanced Research and Development Authority, Development, R, FDA, PRV, Patient, CDKL5, Pharmaceutical industry, Online gambling, Cryptocurrency, EU

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2021.

Key Points: 
  • Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2021.
  • A Rare Pediatric Disease Priority Review Voucher (PRV) was awarded to Marinus by the U.S. Food and Drug Administration upon approval of ZTALMY.
  • The company intends to monetize the PRV to fund on-going operations, including continued clinical development and commercialization efforts for ganaxolone.
  • At December 31, 2021, the company had cash, cash equivalents, and short-term investments of $122.9 million, compared to $140.0 million at December 31, 2020.

Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial

Retrieved on: 
Monday, March 14, 2022
Arrestin, NOAEL, Epilepsy, Mouse, Drug development, Toxicology, Company, No-observed-adverse-effect level, Psilocybin, Ingestive behaviors, Cannabidiol, FDA, Laboratory, Temperature, Seizure, GLP, Depression, CSE, Pain, Status epilepticus, Brain, Nicotine, Impulsivity, GLOBE, 2-Methyl-5-hydroxytryptamine, Dog, Patient, PTSD, Bright Minds In Action Learning Village, Central nervous system, Disorder, Population, Lists of diseases, Dravet syndrome, DS, Fenfluramine, SCN1A, Pharmaceutical industry, Serotonin

The studies were conducted by the Companys contract research partner, ITR Laboratories Canada in Baie dUrf, Qubec, Canada.

Key Points: 
  • The studies were conducted by the Companys contract research partner, ITR Laboratories Canada in Baie dUrf, Qubec, Canada.
  • Were encouraged and hopeful that BMB-101 will provide a new and effective approach to its treatment.
  • These data, generated in our 28-day toxicology studies, provide further support for advancing our clinical program, concluded Dr. Shreeniwas.
  • We are delighted to have completed this important milestone, which is pivotal for supporting our forthcoming first-in-human clinical trial, currently expected to begin in 2Q22, said Ian McDonald, Bright Minds Chief Executive Officer.